Vistagen's fasedienol misses PALISADE-4 goal; subgroup signal seen
The Phase 3 trial of intranasal fasedienol missed its primary anxiety-relief endpoint in social anxiety disorder, and Vistagen is now pointing to a post-hoc subgroup and a redesigned pathway.
Executive Summary
- Vistagen's Phase 3 trial of intranasal fasedienol in social anxiety disorder missed its primary endpoint in the full study population, while a subgroup of patients with the most severe symptoms showed a nominally separation from placebo.
- The miss unwinds the acute single-dose treatment claim the fasedienol program was built to support, and the company is now shifting toward a different primary measure and a redesigned trial to seek a regulatory path forward.
- The positive signal the company is emphasizing came from a subgroup analysis defined after the trial closed, not from the endpoint the study was designed and powered to test.
- Tolerability held up consistent with the drug's prior placebo-controlled trials, the one unambiguous positive to come out of the readout.
The result
PALISADE-4 tested a single dose of fasedienol nasal spray against placebo in adults with social anxiety disorder, using the Subjective Units of Distress Scale (SUDS) during a simulated public-speaking challenge as its primary endpoint. In the full 238-patient population, fasedienol reduced SUDS scores by 9.5 points from baseline against an 11.4-point reduction on placebo, a 1.9-point difference that was not statistically significant (p=0.427). Secondary endpoints, the Clinical Global Impression Scale of Improvement and Patient Global Impression of Change, showed no treatment difference either. NCT06615557+1Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)NCT06615557Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety DisorderJun 30, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The subgroup
In a post-hoc analysis of 123 patients who entered the trial with the most severe social anxiety, defined by a baseline Liebowitz Social Anxiety Scale (LSAS) score of 95 or higher, fasedienol produced a 12.8-point SUDS reduction against a 3.7-point reduction on placebo, a 9.1-point gap that reached nominal significance (p=0.036). That comparison was not the trial's prespecified primary analysis. Vistagen's chief medical officer, Angel Angelov, said the primary result "were not what we had hoped for," while pointing to the 9.1-point subgroup gap as a reason to pursue further study. VistagenVistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety DisorderJun 30, 2026
Safety
Vistagen described fasedienol's safety and tolerability in PALISADE-4 as consistent with its earlier placebo-controlled trials. That reading holds up against the broader fasedienol program: an open-label extension of the prior PALISADE-3 trial, covering 341 patients on as-needed dosing, reported a 2.6% discontinuation rate and no drug-related serious adverse events through four months. VistagenVistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety DisorderJun 30, 2026
The pivot
Vistagen said it now plans to meet with the FDA to discuss a registrational pathway built around a single, future multi-dose Phase 3 trial using the LSAS, rather than the acute-dose SUDS measure PALISADE-4 was built to test, citing the drug's earlier positive PALISADE-2 result and its aggregate safety data as support. That shift moves the primary regulatory case from a trial that already read out negative to a trial that has not yet been designed or run. VistagenVistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety DisorderJun 30, 2026
Program context
PALISADE-4 was fasedienol's fourth Phase 3 trial in social anxiety disorder, running alongside PALISADE-3, which is active but not recruiting, and a Phase 2 repeat-dose study still recruiting. The trial completed enrollment at its 238-patient target with no material deviation from plan, and its primary completion date moved by 202 days across two revisions before landing on April 21, 2026, changes that tracked routine registry updates rather than a signal the readout itself was compromised. NCT06615557Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)NCT06615557
Where it sits
Social anxiety disorder has a crowded Phase 2/3 pipeline built almost entirely on small-molecule mechanisms distinct from fasedienol's intranasal pherine approach, including Vanda Pharmaceuticals' VQW-765 and Newleos Therapeutics' NTX-1472, both still in trials targeting on-demand or acute anxiety relief. Paroxetine and venlafaxine remain approved daily oral options for social anxiety disorder, leaving an on-demand, single-dose treatment as the unmet niche fasedienol was designed to fill. A negative primary result in this trial, its second placebo-controlled miss after an earlier positive PALISADE-2 readout, raises the bar for what a fifth trial built around a different endpoint would need to show to establish that the drug's effect is real and reproducible rather than confined to specific trial conditions.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.